CN115737687A - 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 - Google Patents
普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 Download PDFInfo
- Publication number
- CN115737687A CN115737687A CN202211264902.7A CN202211264902A CN115737687A CN 115737687 A CN115737687 A CN 115737687A CN 202211264902 A CN202211264902 A CN 202211264902A CN 115737687 A CN115737687 A CN 115737687A
- Authority
- CN
- China
- Prior art keywords
- clostridium
- bacterial solution
- heart disease
- coronary heart
- operation box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193403 Clostridium Species 0.000 title claims abstract description 61
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000000243 solution Substances 0.000 claims description 41
- 230000001580 bacterial effect Effects 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 10
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- 239000012154 double-distilled water Substances 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000012138 yeast extract Substances 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 230000007613 environmental effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000000709 aorta Anatomy 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 206010002388 Angina unstable Diseases 0.000 description 4
- 208000007718 Stable Angina Diseases 0.000 description 4
- 208000007814 Unstable Angina Diseases 0.000 description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 241001608234 Faecalibacterium Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000043362 Megamonas Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000385060 Prevotella copri Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 241000702460 Akkermansia Species 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 206010058177 Hyperkinetic heart syndrome Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000023505 abnormal feces Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211264902.7A CN115737687A (zh) | 2022-10-16 | 2022-10-16 | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211264902.7A CN115737687A (zh) | 2022-10-16 | 2022-10-16 | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115737687A true CN115737687A (zh) | 2023-03-07 |
Family
ID=85351634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211264902.7A Pending CN115737687A (zh) | 2022-10-16 | 2022-10-16 | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115737687A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190015465A1 (en) * | 2016-02-04 | 2019-01-17 | Universiteit Gent | Use of microbial communities for human and animal health |
CN115093999A (zh) * | 2022-06-24 | 2022-09-23 | 江南大学 | 一株可改善血脂紊乱的普拉梭菌及其应用 |
-
2022
- 2022-10-16 CN CN202211264902.7A patent/CN115737687A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190015465A1 (en) * | 2016-02-04 | 2019-01-17 | Universiteit Gent | Use of microbial communities for human and animal health |
CN115093999A (zh) * | 2022-06-24 | 2022-09-23 | 江南大学 | 一株可改善血脂紊乱的普拉梭菌及其应用 |
Non-Patent Citations (4)
Title |
---|
ZHUYE JIE 等: "The gut microbiome in atherosclerotic cardiovascular disease", 《NATURE COMMUNICATIONS》, vol. 8, no. 845, pages 1 - 12 * |
张春霞;杨云梅;: "产丁酸菌与老年代谢性疾病的相关研究", 中华保健医学杂志, no. 01, pages 53 - 54 * |
李翔;袁宇;: "冠心病患者肠道菌群变化的研究", 心电与循环, no. 01, pages 1 - 7 * |
黄晓丽;张新;费先艳;陈兆桂;于成功;: "普拉梭菌上清对葡聚糖酸钠诱导的溃疡性结肠炎小鼠Th17细胞及IL-17A的影响", 中南大学学报(医学版), no. 12, pages 1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Metwaly et al. | Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders | |
Fan et al. | Gut microbiota in human metabolic health and disease | |
Knox et al. | The gut microbiome as a target for IBD treatment: are we there yet? | |
Hall et al. | Human genetic variation and the gut microbiome in disease | |
Horie et al. | Comparative analysis of the intestinal flora in type 2 diabetes and nondiabetic mice | |
Wellman et al. | Intestinal epithelial sirtuin 1 regulates intestinal inflammation during aging in mice by altering the intestinal microbiota | |
Mei et al. | Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls | |
Tian et al. | Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota | |
CN105378739B (zh) | 鉴定有发生2型糖尿病风险的人 | |
Katsimichas et al. | Non-ischemic heart failure with reduced ejection fraction is associated with altered intestinal microbiota | |
Cox et al. | The nonfermentable dietary fiber hydroxypropyl methylcellulose modulates intestinal microbiota | |
Li et al. | Chlorophyll supplementation in early life prevents diet‐induced obesity and modulates gut microbiota in mice | |
Kang et al. | Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone | |
Rhoades et al. | Maturation of the infant rhesus macaque gut microbiome and its role in the development of diarrheal disease | |
CN107949393A (zh) | 细菌组合物及其应用方法 | |
WO2019149247A1 (zh) | 用于2型糖尿病的生物标志物及其用途 | |
Marvasti et al. | The first report of differences in gut microbiota composition between obese and normal weight Iranian subjects | |
Lu et al. | Fecal microbiome data distinguish liver recipients with normal and abnormal liver function from healthy controls | |
Wang et al. | Effect of a probiotic combination in an experimental mouse model and clinical patients with chronic kidney disease: a pilot study | |
Wu et al. | Effects of multispecies probiotic on intestinal microbiota and mucosal barrier function of neonatal calves infected with e. Coli k99 | |
Zhang et al. | Study on the Intervention Effect of Qi Gong Wan Prescription on Patients with Phlegm‐Dampness Syndrome of Polycystic Ovary Syndrome Based on Intestinal Flora | |
Hong et al. | Impacts of enriched human milk cells on fecal metabolome and gut microbiome of premature infants with stage i necrotizing enterocolitis: a pilot study | |
CN115737687A (zh) | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 | |
WO2021059241A1 (en) | Microbiome compositions and methods of treatment of atopic diseases | |
Wang et al. | Effects of Micro-Ecological Enteral Nutrition on Systemic Inflammatory Response, Bacterial Translocation, and Immune Function in Patients with Severe Acute Pancreatitis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xie Xiang Inventor after: Yang Haitao Inventor after: Liu Jingkun Inventor after: Zheng Yingying Inventor after: Yang Yi Inventor after: Wu Tingting Inventor after: Hou Xiangeng Inventor after: Ning Yi Inventor after: Jiang Zhihui Inventor before: Yang Haitao Inventor before: Xie Xiang Inventor before: Liu Jingkun Inventor before: Zheng Yingying Inventor before: Yang Yi Inventor before: Wu Tingting Inventor before: Hou Xiangeng Inventor before: Ning Yi Inventor before: Jiang Zhihui |